14
May

At first glance, you might suspect that Gene Signal’s Phase III study of its lead drug for a rare eye disease was a roaring success. But if you dig down into its release today, you’ll find that the drug flunked its primary endpoint–an inconvenient truth that is dismissed as a mere triviality.

…read more

Source: PhIII eye drug failure? Not at all, says an optimistic Gene Signal

    

0 No comments